Logo

GlaxoSmithKline Extends Use of InforSense Platform

Jul 28, 2008
NEW YORK (GenomeWeb News) – InforSense said on Friday that GlaxoSmithKline has signed a contract to continue using the firm’s InforSense platform for another three years.
 
The London-based firm said that around 800 users within the drug giant are currently using the platform, which is a workflow-management software tool.
 
Terms of the deal were not disclosed.

Breaking News
The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.